In particular, this biomarker could be employed to identify potential responders in upcoming disease-modifying phase II clinical trials (mainly BACE inhibitors or other targeted anti-amyloid therapies), identifying eligible participants at an earlier stage of cognitive decline, before the processes of amyloidosis begin. The gene discussed is BACE1; the disease is Mental deterioration.